 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Enzon Pharmaceuticals (OTCMKTS:ENZN  Get Free Report) and ProKidney (NASDAQ:PROK  Get Free Report) are both medical companies, but which is the superior investment? We will contrast the...

Enzon Pharmaceuticals (OTCMKTS:ENZN) & ProKidney (NASDAQ:PROK) Critical Contrast

ProKidney Corp. (NASDAQ:PROK Get Free Report) has received an average rating of Moderate Buy from the seven brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the ...

ProKidney Corp. (NASDAQ:PROK) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of ProKidney Corp. (NASDAQ:PROK  Get Free Report) have been assigned an average recommendation of Moderate Buy from the seven ratings firms that are presently covering the...

Brokerages Set ProKidney Corp. (NASDAQ:PROK) Target Price at $15.33

In trading on Wednesday, shares of ProKidney Corp (PROK) crossed below their 200 day moving average of 10.55, changing hands as low as 10.13 per share. ProKidney Corp shares are currently...

Notable Two Hundred Day Moving Average Cross - PROK

WINSTON-SALEM, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ( ProKidney or the Company ), a leading late clinical-stage cellular therapeutics company focused on...

ProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights

Investors considering a purchase of ProKidney Corp (PROK) shares, but tentative about paying the going market price of 12.31/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2024 put...

Commit To Buy ProKidney Corp At $10, Earn 26.5% Annualized Using Options

ProKidney Corp. (NASDAQ:PROK  Get Free Report) has been assigned a consensus recommendation of Moderate Buy from the seven brokerages that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and six have ...

ProKidney Corp. (NASDAQ:PROK) Given Consensus Rating of "Moderate Buy" by Brokerages

BTIG Research assumed coverage on shares of ProKidney (NASDAQ:PROK  Free Report) in a report released on Monday, Marketbeat.com reports. The firm issued a buy rating and a $16.00 target price on the stock. ProKidney Stock Performance NASDAQ:PROK opened at $11.65 on Monday. ProKidney has a 1 ...

ProKidney (NASDAQ:PROK) Coverage Initiated by Analysts at BTIG Research

WINSTON-SALEM, N.C., July 18, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (ProKidney or the Company), a leading late clinical-stage cellular therapeutics company focused on preserving kidney function in patients suffering from chronic kidney disease (CKD), today announced it has closed ...

ProKidney Announces Closing of Purchase of Manufacturing Facility in Greensboro, NC

- Brings more than 20 years of academic and industry experience with extensiveexpertise in kidney disease - WINSTON-SALEM, N.C., July 17, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (ProKidney or the Company), a leading late clinical-stage cellular therapeutics company focused on chronic...

ProKidney Appoints Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease (CKD), shifting the emphasis away from management of kidney failure, to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells (SRCs) prepared from a patient’s own, autologous, renal cells. The company is headquartered in Winston-Salem, NC.

Watchers	95
52-Wk Low	$4.55
52-Wk High	$14.19

Market Cap	$288.86M
Volume (M)	285,344.00
52-Wk High	$14.19
52-Wk Low	$4.55

PROK ProKidney Corp

About

Feed

News

Sentiment

Earnings

Fundamentals